Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Date
2008
Author
Havrdova, Eva
Limmroth, Volker
Polman, Chris H.
Kappos, Ludwig
Schmierer, Klaus
Yousry, Tarek A.
Yang, Minhua
ERAKSOY, Mefküre
Meluzinova, Eva
Rektor, Ivan
Dawson, Katherine T.
Sandrock, Alfred W.
O'Neill, Gilmore N.
Gold, Ralf
Miller, David H.
MacManus, David G.
Metadata
Show full item record
Abstract
Background Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis.
URI
http://hdl.handle.net/20.500.12627/179589
https://doi.org/10.1016/s0140-6736(08)61619-0
Collections